
Please try another search
lululemon athletica inc. (NASDAQ:LULU) is slated to report third-quarter fiscal 2017 results on Dec 6. The question lingering in investors’ minds is whether this yoga-inspired athletic apparel retailer will be able to deliver positive earnings surprise in the to-be-reported quarter.
In the trailing four quarters, the company has outperformed the Zacks Consensus Estimate by an average of 8.5%. Also, it has pulled off positive earnings surprise of 11.4% in the previous quarter. Let’s see how things are shaping up prior to this announcement.
What to Expect?
The Zacks Consensus Estimate for the quarter under review is pegged at 52 cents, reflecting a year-over-year growth of 10.3%. However, the estimate has been stable in the last 30 days. Further, analysts polled by Zacks expect revenues of $611.4 million, up about 12.3% from the year-ago quarter.
lululemon has an Earnings ESP of -0.50% and Zacks Rank #4 (Sell). This combination makes our surprise prediction impossible. As it is we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks With Favorable Combination
Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat.
Dollar General Corporation (NYSE:DG) has an Earnings ESP of +1.46% and Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Zumiez Inc. (NASDAQ:ZUMZ) has an Earnings ESP of +0.69% and Zacks Rank #2.
The Kroger Co. (NYSE:KR) has an Earnings ESP of +3.33% and Zacks Rank #3.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Early in 2025, value stocks emerged as a popular choice among investors seeking market-beating returns. However, factor-based investing strategies can be notoriously difficult to...
Mid-cap stocks don’t get the same headlines as large caps but move aggressively in both directions, creating outsized opportunities for investors. Unlike their mega-cap...
There’s no doubt it’s been a rough couple weeks for stocks: Both the S&P 500 and the tech-focused NASDAQ have wiped out most of this year’s gains, as of this writing. Stocks...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.